Advancing Drug Discovery and Treatment Options With Patients and Citizen Science

This approach not only reduces costs but also enhances the success of clinical trials. What are the advantages and disadvantages of patient-centric and patient-led trials? How can technology help bring patient equity? What does the future hold for patient partnerships to advance scientific and drug discovery?

Register Free: https://www.pharmexec.com/pe/advancing-drug-discovery

Event Overview:

In the realm of healthcare, patients are now more involved in their own care, with easy access to information through the internet and the use of new technologies that empower them to generate and share data. Patients are not only the beneficiaries of scientific knowledge but are creators of scientific knowledge. As a result, pharma companies are recognizing the potential benefits of engaging with highly motivated patients and patient organizations. This approach not only reduces costs but also enhances the success of clinical trials, especially for rare diseases. This session will delve into the advantages and disadvantages of patient-centric and patient-led trials, how technology can help bring patient equity, and what the future holds for patient partnerships to advance scientific and drug discovery.

Key Learning Objectives:

• How to align incentives and ensure scientific rigor and standards throughout the patient-to-professional partnership
• FAIR and CARE principles and how to ensure proper data standards across many data constituents, collaborations, and frameworks.
• Discuss what the future holds in terms of developing cross-industry engagement models and frameworks and the role government and federal play.

Who Should Attend:

This webinar is applicable to:

• Clinical researchers, academic researchers, data scientists, and clinical decision teams responsible for:
  • Research data computing and planning
  • Clinical development planning and study design
  • Management of patients and measurement of clinical outcomes
  • Clinical data management, collecting and evaluating trial metrics
  • Project management of studies, process optimization, and operational excellence

Speakers:

AMY SORRELLS
Senior Director
Oracle

Amy Sorrells is a communications professional with more than 25 years of digital communications, content creation, public relations, and marcomms experience spanning numerous industries including technology, healthcare, sports, and media. She currently leads global communications for Oracle’s efforts focused on supporting researchers and research computing. She joined Oracle in May of 2012, as part of an acquisition of technology startup Vitrue. Prior to Oracle, she was a long-time communications consultant, working with numerous technology, healthcare, and media clients. She also served in communications roles with Fox Cable Networks, CNN, Turner Sports, and USA Track & Field. Amy received her bachelor’s degree from Auburn University and her master’s in psychology from the University of Arizona global campus. She currently resides in Atlanta with her husband and two boys.

LAURE HAAK
Founder and CEO
Mighty Red Barn

A neuroscientist by training, Laure Haak has a BS and MS in Biology and PhD in Neuroscience from Stanford University, and she did postdoctoral work at the National Institutes of Health. Her career includes diverse experiences: serving as founding Executive Director of ORCID; leadership roles at Thomson Reuters, The US National Academies, and Science Magazine. She is currently founder and CEO of Mighty Red Barn, a consultancy that supports impact-based organizations building digital infrastructure, and helping research innovators go from discovery to startup. Laure carries on this work as a Research Scholar at the Ronin Institute, and Board Chair of Phoenix Bioinformatics and the Green Bay Chapter of SCORE.

Dr MARK HOFFMAN
Chief Research Information Officer
Children’s Mercy and Children’s Mercy Research Institute

Mark Hoffman, PhD, serves as the Chief Research Information Officer (CRIO) for Children’s Mercy and the Children’s Mercy Research Institute. Dr. Hoffman’s role is to accelerate and improve all types of research at the Children’s Mercy Research Institute through resources such as data, applications, and technology. Dr. Hoffman earned his doctorate in Bacteriology from the University of Wisconsin-Madison. He later joined Cerner as a software engineer where he advanced to the role of Vice President for Genomics and Research. Dr. Hoffman was also part of the faculty at the University of Missouri Kansas City (UMKC) in the Departments of Biomedical and Health Informatics and Pediatrics. His formal training in research and experience in software development have prepared him to connect the needs of researchers to the capabilities of technology. His work is focused on identifying the best capabilities possible to meet rapidly changing requirements in genomics, public health and big data. Dr. Hoffman is an inventor of 22 issued patents, member of the American Academy of Inventors, TED talk alumnus, and an award-winning healthcare product developer.

SCOTT SCHLIEBNER
Principal
Rare Clinical, LLC

Scott Schliebner a strategic, innovative, and commercially oriented life sciences executive with 30 years experience across the biopharma, CRO, medtech, and non-profit sectors. With a strategic and consultative approach to building and growing life science businesses, Scott has developed relationships, partnerships and collaborations that have driven commercial success. Scott’s thought leadership efforts include leveraging RWE/RWD, technological innovation, and patient-focused paradigms to accelerate clinical drug development. Active as a Commercial Officer, Strategic Advisor, Board Member, and mentor, he is passionate about infusing data and innovation into life sciences organizations.

Register Free: https://www.pharmexec.com/pe/advancing-drug-discovery